Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 3, 2025Clinical Cancer ResearchOpen Access

Radiogenomic profiling of prostate tumors prior to external beam radiotherapy converges on a transcriptomic signature of TGF-β activity driving tumor recurrence

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAnson T. KuUSUma ShankavaramSTShana Y. Trostel

Discussion

Loading...

Member takes

Overview

Prospective analysis reveals TGF-β activity predicts biochemical recurrence in prostate cancer patients post-radiotherapy, suggesting personalized treatment approaches.

Key Points

  • TGF-β activity significantly associates with biochemical recurrence in prostate cancer.
  • A novel TGF-β gene signature correlates with prostate tumor characteristics and survival metrics.
  • Patients underwent extensive analysis including microarray and mpMRI, with 6-year follow-up.
  • TGF-β activity may serve as an independent biomarker for treatment planning in prostate cancer.

Cite This Study

Ku et al. (2025) studied this question.

synapsesocial.com/papers/68e02f3cf0e39f13e7fa2485https://doi.org/10.1158/1078-0432.ccr-25-2186
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic Factors Associated with Biochemical Relapse after Radiotherapy in Localized Prostate Cancer: A Retrospective Cohort Study2025
  2. 2Prognostic Factors Associated with Biochemical Relapse After Radiotherapy in Localized Prostate Cancer: A Retrospective Cohort Study2025
  3. 3Development of a prostate cancer biochemical recurrence risk signature using machine learning and motor protein-related genes2025
  4. 4Time to Prostate‐Specific Antigen Failure as a Unique Prognosticator of Overall Survival in Biochemically Recurrent Prostate Cancer Patients Undergoing Radical Prostatectomy2025
  5. 5Genomic Biomarker for Prostate Cancer Focal Therapy: Post Hoc Assessment of a Phase II Clinical Trial2025 · 3 citations